The July 4 agreement combines Sanyou Bio’s AI-driven molecule discovery platforms with Baiyunshan Xihe’s radionuclide production, GMP manufacturing and clinical translation capabilities for precision oncology products.
verifying reliability
No specialized terms available for this topic.